Pediatric Enterococcal Bacteremia: A 12-Year Retrospective Study in a French Pediatric Center.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
14
7
2022
medline:
12
8
2022
entrez:
13
7
2022
Statut:
ppublish
Résumé
Enterococcal bloodstream infections (EBSIs) are rare infections in children associated with 5%-10% of mortality in previous studies. The recent evolution of antimicrobial resistance and therapies require updated data. We conducted an observational retrospective study between January 2008 and December 2019 describing the characteristics of children with EBSI in a French pediatric hospital. All positive Enterococcus spp. blood cultures associated with sepsis symptoms were analyzed. We also compared characteristics of healthcare-associated infections (HAIs) and community-acquired infections (CAIs) and described antimicrobial resistance evolution during this period. In total 74 EBSI were included. Enterococcus faecalis was the most common pathogen (n = 60/74, 81%) followed by Enterococcus faecium (n = 18, 24%), including 4 enterococcal coinfections. EBSIs were mainly associated with central-line associated infection (38%), surgical site infection (14%) or urinary tract infection (11%). An underlying disease was present in 95.9%. However, 4 patients died in the month following the EBSI resulting in a 5.4%, 30-day mortality. All were HAI. HAI (84% of EBSI) was associated with longer bacteremia [31% persistent bacteremia (more than 3 days) versus 0% for CAI; P = 0.029] and more antimicrobial resistance. Amoxicillin resistance is increasing since 2013 in E. faecium (63% in 2013-2019), although high-level gentamicin resistance is stable (19%). Only 1 EBSI due to vancomycin-resistant Enterococcus was described in our cohort, who died. EBSIs are rare infections in children mostly described in children with underlying disease. Healthcare-associated bacteremia is associated with higher rates of resistance and poorer prognosis, requiring the involvement of pediatric infectious disease specialists to improve management.
Sections du résumé
BACKGROUND
Enterococcal bloodstream infections (EBSIs) are rare infections in children associated with 5%-10% of mortality in previous studies. The recent evolution of antimicrobial resistance and therapies require updated data.
METHODS
We conducted an observational retrospective study between January 2008 and December 2019 describing the characteristics of children with EBSI in a French pediatric hospital. All positive Enterococcus spp. blood cultures associated with sepsis symptoms were analyzed. We also compared characteristics of healthcare-associated infections (HAIs) and community-acquired infections (CAIs) and described antimicrobial resistance evolution during this period.
RESULTS
In total 74 EBSI were included. Enterococcus faecalis was the most common pathogen (n = 60/74, 81%) followed by Enterococcus faecium (n = 18, 24%), including 4 enterococcal coinfections. EBSIs were mainly associated with central-line associated infection (38%), surgical site infection (14%) or urinary tract infection (11%). An underlying disease was present in 95.9%. However, 4 patients died in the month following the EBSI resulting in a 5.4%, 30-day mortality. All were HAI. HAI (84% of EBSI) was associated with longer bacteremia [31% persistent bacteremia (more than 3 days) versus 0% for CAI; P = 0.029] and more antimicrobial resistance. Amoxicillin resistance is increasing since 2013 in E. faecium (63% in 2013-2019), although high-level gentamicin resistance is stable (19%). Only 1 EBSI due to vancomycin-resistant Enterococcus was described in our cohort, who died.
CONCLUSIONS
EBSIs are rare infections in children mostly described in children with underlying disease. Healthcare-associated bacteremia is associated with higher rates of resistance and poorer prognosis, requiring the involvement of pediatric infectious disease specialists to improve management.
Identifiants
pubmed: 35830518
doi: 10.1097/INF.0000000000003631
pii: 00006454-202209000-00008
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e346-e350Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Schloissnig S, Arumugam M, Sunagawa S, et al. Genomic variation landscape of the human gut microbiome. Nature. 2013;493:45–50.
Butel MJ, Waligora-Dupriet AJ, Wydau-Dematteis S. The developing gut microbiota and its consequences for health. J Dev Orig Health Dis. 2018;9:590–597.
Oren A, Garrity GM. Notification of changes in taxonomic opinion previously published outside the IJSEM. Int J Syst Evol Microbiol. 2020;70:9–10.
Larru B, Gong W, Vendetti N, et al. Bloodstream infections in hospitalized children: epidemiology and antimicrobial susceptibilities. Pediatr Infect Dis J. 2016;35:507–510.
SPF. Enquête nationale de prévalence des infections nosocomiales et des traitements anti-infectieux en établissements de santé, mai-juin 2017. Available at: https://www.santepubliquefrance.fr/import/enquete-nationale-de-prevalence-des-infections-nosocomiales-et-des-traitements-anti-infectieux-en-etablissements-de-sante-mai-juin-2017 . Accessed July 22, 2021.
Zasowski EJ, Claeys KC, Lagnf AM, et al. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis. 2016;62:1242–1250.
Billington EO, Phang SH, Gregson DB, et al. Incidence, risk factors, and outcomes for Enterococcus spp. blood stream infections: a population-based study. Int J Infect Dis. 2014;26:76–82.
Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore). 1995;74:191–200.
Das I, Gray J. Enterococcal bacteremia in children: a review of seventy-five episodes in a pediatric hospital. Pediatr Infect Dis J. 1998;17:1154–1158.
Furuichi M, Furuichi M, Horikoshi Y, et al. Infectious diseases consultation improves treatment and decreases mortality by enterococcal bacteremia in children. Pediatr Infect Dis J. 2018;37:856–860.
Christie C, Hammond J, Reising S, et al. Clinical and molecular epidemiology of enterococcal bacteremia in a pediatric teaching hospital. J Pediatr. 1994;125:392–399.
Boulanger JM, Ford-Jones EL, Matlow AG. Enterococcal bacteremia in a pediatric institution: a four-year review. Rev Infect Dis. 1991;13:847–856.
Guzman Prieto AM, van Schaik W, Rogers MR, et al. Global emergence and dissemination of enterococci as nosocomial pathogens: attack of the clones? Front Microbiol. 2016;7:788.
ECDC. SURVEILLANCE REPORT. Surveillance of antimicrobial resistance in Europe 2018. 110. Available at: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018 . Accessed July 22, 2021.
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–332.
Medistica. Pvalue.Io. A graphic user interface to the R statistical analysis software for scientific medical publications. 2020. Available at: https://www.pvalue.io/fr/ Accessed July 22, 2021.
Rosselli Del Turco E, Bartoletti M, Dahl A, et al. How do I manage a patient with enterococcal bacteraemia? Clin Microbiol Infect. 2021;27:364–371.
Berge A, Krantz A, Östlund H, et al. The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary. Infection. 2019;47:45–50.
Bouza E, Kestler M, Beca T, et al.; Grupo de Apoyo al Manejo de la Endocarditis. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis. 2015;60:528–535.
Top J, Willems R, Blok H, et al. Ecological replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus faecium. Clin Microbiol Infect. 2007;13:316–319.
Beganovic M, Luther MK, Rice LB, et al. A review of combination antimicrobial therapy for enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis. 2018;67:303–309.
Peiffer-Smadja N, Guillotel E, Luque-Paz D, et al. In vitro bactericidal activity of amoxicillin combined with different cephalosporins against endocarditis-associated Enterococcus faecalis clinical isolates. J Antimicrob Chemother. 2019;74:3511–3514.
Habib G, Lancellotti P, Antunes MJ, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–3128.
Cobos-Carrascosa E, Soler-Palacín P, Nieves Larrosa M, et al. Staphylococcus aureus bacteremia in children: changes during eighteen years. Pediatr Infect Dis J. 2015;34:1329–1334.
Kaplan SL, Mason EO Jr, Wald E, et al. Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis J. 2002;21:141–147.
Suppli M, Aabenhus R, Harboe ZB, et al. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect. 2011;17:1078–1083.